Elutia (ELUT) Stock Overview
A commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ELUT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.7k
23
2
55
Elutia Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$2.64 |
| 52 Week Low | US$0.50 |
| Beta | 0.71 |
| 1 Month Change | -13.68% |
| 3 Month Change | -0.98% |
| 1 Year Change | -50.49% |
| 3 Year Change | -57.92% |
| 5 Year Change | -91.28% |
| Change since IPO | -93.03% |
Recent News & Updates
Recent updates
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Feb 15
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
Dec 06ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
Oct 13Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Aug 29US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
Aug 19FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
Jun 18
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Jan 04Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 20Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Jun 28News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
Mar 10Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Shareholder Returns
| ELUT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.6% | -2.4% | 0.8% |
| 1Y | -50.5% | 27.4% | 27.8% |
Return vs Industry: ELUT underperformed the US Biotechs industry which returned 27.4% over the past year.
Return vs Market: ELUT underperformed the US Market which returned 27.8% over the past year.
Price Volatility
| ELUT volatility | |
|---|---|
| ELUT Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ELUT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELUT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 26 | Randy Mills | elutia.com |
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
Elutia Inc. Fundamentals Summary
| ELUT fundamental statistics | |
|---|---|
| Market cap | US$44.65m |
| Earnings (TTM) | -US$15.87m |
| Revenue (TTM) | US$12.29m |
3.6x
P/S Ratio-2.8x
P/E RatioIs ELUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELUT income statement (TTM) | |
|---|---|
| Revenue | US$12.29m |
| Cost of Revenue | US$5.70m |
| Gross Profit | US$6.60m |
| Other Expenses | US$22.47m |
| Earnings | -US$15.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 14, 2026
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 53.66% |
| Net Profit Margin | -129.11% |
| Debt/Equity Ratio | 0% |
How did ELUT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 10:52 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elutia Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |